Tvardi Therapeutics, Inc. filed an amendment to its prior 8-K report on May 13, 2025, updating financial details and management analysis following its merger completed on April 15, 2025. The filing includes unaudited financial statements for the quarter ended March 31, 2025, reflecting the amalgamation with Private Tvardi.